D-cycloserine for the treatment of ataxia in spinocerebellar degeneration

Masafumi Ogawa, Hiroshi Shigeto, Toshiyuki Yamamoto, Yasushi Oya, Keiji Wada, Toru Nishikawa, Mitsuru Kawai

研究成果: Contribution to journalArticle査読

30 被引用数 (Scopus)

抄録

We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.

本文言語英語
ページ(範囲)53-56
ページ数4
ジャーナルJournal of the Neurological Sciences
210
1-2
DOI
出版ステータス出版済み - 6 15 2003
外部発表はい

All Science Journal Classification (ASJC) codes

  • 神経学
  • 臨床神経学

フィンガープリント

「D-cycloserine for the treatment of ataxia in spinocerebellar degeneration」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル